Meeting
2021 ASCO Annual Meeting
Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML.
Authors
Vinod Pullarkat
City of Hope Comprehensive Cancer Center, Duarte, CA
Vinod Pullarkat , Mark J. Levis , Gabriel N. Mannis , Stephen Anthony Strickland , Tara L. Lin , Stefan Faderl , Divya Chakravarthy , Vijayalakshmi Chandrasekaran , Ronald Cheung , Harry Paul Erba
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT04075747
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7026)
DOI
10.1200/JCO.2021.39.15_suppl.7026
Abstract #
7026
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.
First Author: James K. McCloskey
Poster
2022 ASCO Annual Meeting
Lower-intensity CPX-351 + venetoclax for patients with newly diagnosed AML who are unfit for intensive chemotherapy.
First Author: Geoffrey L. Uy
Poster
2020 ASCO Virtual Scientific Program
Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy (IC).
First Author: Tara L. Lin
Poster
2019 ASCO Annual Meeting
Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed FLT3 mutated AML.
First Author: Richard M. Stone